Pharmesis International (SGX:BFK) ROCE % : -9.42% (As of Jun. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Pharmesis International ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pharmesis International's annualized ROCE % for the quarter that ended in Jun. 2024 was -9.42%.

Pharmesis International ROCE % Historical Data

The historical data trend for Pharmesis International's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmesis International ROCE % Chart

Pharmesis International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-22.22

-8.18

5.35

-3.51

-6.88

Pharmesis International Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial															-8.61	1.38	-0.84	-12.97	-9.42

Pharmesis International ROCE % Calculation

Pharmesis International's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-0.744	/	( ( (18.982 - 7.677)	+	(16.025 - 5.714) )	/ 2 )
	=	-0.744	/	( (11.305	+	10.311)	/ 2 )
	=	-0.744	/	10.808
	=	-6.88 %

Pharmesis International's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-0.956	/	( ( (16.025 - 5.714)	+	(14.7 - 4.705) )	/ 2 )
	=	-0.956	/	( ( 10.311	+	9.995 )	/ 2 )
	=	-0.956	/	10.153
	=	-9.42 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Pharmesis International (SGX:BFK) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pharmesis International ROCE % Related Terms

Thank you for viewing the detailed overview of Pharmesis International's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmesis International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmesis International Ltd (SGX:BFK) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

5 Kallang Sector, No. 03-02, Singapore, SGP, 349279

Website

https://www.pharmesis.com

Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution. The company derives revenue from the sale of medicines to domestic customers in China.

Pharmesis International Headlines

From GuruFocus

Certain BlackRock Municipal Closed-End Funds Announce Variable Rate Muni Term Preferred Shares Actions

By Business Wire • 11-02-2023